JPMorgan analyst Anupam Rama raised his price target for MyoKardia heading into the Phase 3 EXPLORER-HCM results of mavacamten in obstructive hypertrophic cardiomyopathy. The analyst continues to believe that the EXPLORER study has a high probability of success. On positive results, Rama sees MyoKardia shares going to the $100-$115 level, or 40%-65% upside from current levels. And while the downside risk is substantive at 70%-85% given the binary nature of the event, this is a low probability, Rama tells investors in a research note. The analyst reiterates an Overweight rating on the shares.